- cafead Nov 04, 2021 at 10:42: AM
via As the third player to enter the BTK realm, BeiGene has had its eyes fixated on AbbVie and Johnson & Johnson’s market leader Imbruvica. After clinical wins in smaller indications, the Chinese-American biotech has once again posted competitive data for Brukinsa—this time in the all-important newly diagnosed leukemia.
article source
article source